Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Overseas product sales increased, mainly because the sales recognition period for Qinlock extended from 9 months in the previous fiscal year to 12 months in the current fiscal year. Royalty and other revenue also grew due to higher royalty income. Domestic product sales declined, affected by intensifying competition and the entry of generic products for Forxiga tablets. Operating profit increased due to cost of sales remaining largely unchanged from the previous fiscal year and more efficient expenses.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥515,785 million (YoY +5.9%) |
| Operating profit | ¥92,236 million (YoY +54.4%) |
| Ordinary income | ¥92,654 million (YoY +56.2%) |
| Profit attributable to owners of the parent | ¥69,767 million (YoY +39.4%) |
| Net income per share | ¥148.49 |
| Operating Margin | 17.9% |
| Equity ratio | End of the current fiscal period 76.9 / End of previous period 73.5 |
| Total assets | ¥1,106,515 million |
| Net assets | ¥856,643 million |
| Cash flows from operating activities | ¥136,821 million |
| Cash flows from investing activities | ¥-39,860 million |
| Cash flows from financing activities | ¥-65,493 million |
| Cash and cash equivalents at end of period | ¥237,046 million |
| Full-year earnings forecast | Net Sales ¥455,000 million (YoY -11.8%) / Operating profit ¥94,000 million (YoY +1.9%) / Ordinary income ¥94,000 million (YoY +1.5%) / Net income ¥71,000 million (YoY +1.8%) |
| Annual Dividend Forecast | ¥80 → ¥80（0.0%） |
| Payout ratio | Current fiscal year 53.9 % / Next-year forecast 52.9 % |
| Shareholder Return Policy | A progressive policy of maintaining or increasing the annual dividend. The company aims to pay dividends with a target payout ratio of approximately 40%. |
| Regional sales | Region Japan / Current fiscal year ¥287,085 million / Previous period ¥295,247 million, Region United States / Current fiscal year ¥197,061 million / Previous period ¥167,048 million, Region Asia / Current fiscal year ¥17,719 million / Previous period ¥16,343 million, Region Europe / Current fiscal year ¥12,324 million / Previous period ¥7,503 million, Region Other / Current fiscal year ¥1,595 million / Previous period ¥729 million |
| Depreciation and amortization | ¥37,752 million |
| Impairment loss | ¥2,200 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name Ono Global Reinsurance, Inc. / Excluded Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and securities analysts |
| Issued Shares at Period-End | 498,692,800 |
| Treasury Shares at Period-End | 28,785,489 |
| Factors Behind Changes in Business Performance | Overseas product sales increased, mainly because the sales recognition period for Qinlock extended from 9 months in the previous fiscal year to 12 months in the current fiscal year. Royalty and other revenue also grew due to higher royalty income. Domestic product sales declined, affected by intensifying competition and the entry of generic products for Forxiga tablets. Operating profit increased due to cost of sales remaining largely unchanged from the previous fiscal year and more efficient expenses. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue grew due to higher sales of overseas products, the inclusion of 12 months of sales of products from Deciphera, compared with 9 months in the previous fiscal year, and increased royalty income. In contrast, domestic product sales declined due to intensifying competition and the entry of generic products for Forxiga tablets. Operating profit benefited from higher revenue, cost of sales remaining largely unchanged from the previous fiscal year, and more efficient expenses. For the next fiscal year, the company expects sales and expenses to decline following the end of the co-promotion agreement for Forxiga tablets, while one-off expenses recorded in the current fiscal year are not expected to recur.